Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study

Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto

Research output: Contribution to journalArticle

Abstract

Objective: This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC). Methods: The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8%) and 46 (74.2%) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively. Results: The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9% [− 64.5 to 13.0%] and − 30.7% [− 52.8 to 10.9%], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95% confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95% CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95% CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. Conclusions: 3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalCancer chemotherapy and pharmacology
Volume84
Issue number3
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Castration
Prostatic Neoplasms
Hazards
Safety
Confidence Intervals
Prostate-Specific Antigen
Treatment Failure
cabazitaxel
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer : a multi-institutional study. / Shiota, Masaki; Nakamura, Motonobu; Yokomizo, Akira; Tomoda, Toshihisa; Sakamoto, Naotaka; Seki, Narihito; Hasegawa, Shuji; Yunoki, Takakazu; Harano, Masahiko; Kuroiwa, Kentaro; Eto, Masatoshi.

In: Cancer chemotherapy and pharmacology, Vol. 84, No. 3, 01.09.2019, p. 561-566.

Research output: Contribution to journalArticle

Shiota, M, Nakamura, M, Yokomizo, A, Tomoda, T, Sakamoto, N, Seki, N, Hasegawa, S, Yunoki, T, Harano, M, Kuroiwa, K & Eto, M 2019, 'Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study', Cancer chemotherapy and pharmacology, vol. 84, no. 3, pp. 561-566. https://doi.org/10.1007/s00280-019-03874-7
Shiota, Masaki ; Nakamura, Motonobu ; Yokomizo, Akira ; Tomoda, Toshihisa ; Sakamoto, Naotaka ; Seki, Narihito ; Hasegawa, Shuji ; Yunoki, Takakazu ; Harano, Masahiko ; Kuroiwa, Kentaro ; Eto, Masatoshi. / Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer : a multi-institutional study. In: Cancer chemotherapy and pharmacology. 2019 ; Vol. 84, No. 3. pp. 561-566.
@article{501f5a5444744f3cb5b9e86a9ffd1407,
title = "Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer: a multi-institutional study",
abstract = "Objective: This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC). Methods: The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8{\%}) and 46 (74.2{\%}) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively. Results: The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9{\%} [− 64.5 to 13.0{\%}] and − 30.7{\%} [− 52.8 to 10.9{\%}], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95{\%} confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95{\%} CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95{\%} CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. Conclusions: 3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.",
author = "Masaki Shiota and Motonobu Nakamura and Akira Yokomizo and Toshihisa Tomoda and Naotaka Sakamoto and Narihito Seki and Shuji Hasegawa and Takakazu Yunoki and Masahiko Harano and Kentaro Kuroiwa and Masatoshi Eto",
year = "2019",
month = "9",
day = "1",
doi = "10.1007/s00280-019-03874-7",
language = "English",
volume = "84",
pages = "561--566",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer

T2 - a multi-institutional study

AU - Shiota, Masaki

AU - Nakamura, Motonobu

AU - Yokomizo, Akira

AU - Tomoda, Toshihisa

AU - Sakamoto, Naotaka

AU - Seki, Narihito

AU - Hasegawa, Shuji

AU - Yunoki, Takakazu

AU - Harano, Masahiko

AU - Kuroiwa, Kentaro

AU - Eto, Masatoshi

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective: This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC). Methods: The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8%) and 46 (74.2%) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively. Results: The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9% [− 64.5 to 13.0%] and − 30.7% [− 52.8 to 10.9%], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95% confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95% CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95% CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. Conclusions: 3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.

AB - Objective: This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC). Methods: The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8%) and 46 (74.2%) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively. Results: The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9% [− 64.5 to 13.0%] and − 30.7% [− 52.8 to 10.9%], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95% confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95% CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95% CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. Conclusions: 3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.

UR - http://www.scopus.com/inward/record.url?scp=85066157705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066157705&partnerID=8YFLogxK

U2 - 10.1007/s00280-019-03874-7

DO - 10.1007/s00280-019-03874-7

M3 - Article

AN - SCOPUS:85066157705

VL - 84

SP - 561

EP - 566

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -